Clinical Trials on Carcinome papillaire de la thyroïde

Total 510 results

Fondazione I.R.C.C.S. Istituto Neurologico Carlo...
Ministry of Health, Italy

Completed

Subthalamic Stimulation in Tourette's Syndrome (STN-DBSinTS)

Tourette Syndrome | Tourette's Syndrome | Tourette Disorder | Gilles de la Tourette Syndrome

Italy
Hoffmann-La Roche

Completed

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Endocrine System Diseases | Gastrointestinal Neoplasms | Neoplasms, Germ Cell and Embryonal | Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung | Respiratory Tract... and other conditions

France, Spain, United States, Korea, Republic of, United Kingdom, Taiwan, China, Belgium, Singapore, Netherlands, Germany, Italy, Hong Kong
Institut National de la Santé Et de la Recherche...

Terminated

Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome (rTMSPPCGT)

Tics | Gilles de la Tourette Syndrome

France
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Unresectable Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma | Metastatic Papillary Renal Cell Carcinoma | Locally Advanced Papillary Renal Cell Carcinoma

United States, Canada
Fidia Farmaceutici s.p.a.

Completed

ONCOFID-P-B in the Intravescical Therapy of Patients With Non-muscle Invasive Cancer of the Bladder.

Non-Invasive Papillary Carcinoma of Bladder

Spain, Germany, Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Squamous Cell Carcinoma | Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVA Thyroid Gland...

United States
Australian and New Zealand Urogenital and Prostate...

Recruiting

ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) (UNICAB)

Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell Carcinoma

Australia
Australian and New Zealand Urogenital and Prostate...
Bristol-Myers Squibb

Active, not recruiting

Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) (UNISoN)

Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation Carcinoma

Australia
Saint Petersburg State University, Russia

Withdrawn

Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma by AJCC V8 Stage

Russian Federation
National Cancer Institute (NCI)

Completed

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Stage III Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVC Differentiated Thyroid Gland Carcinoma... and other conditions

United States, Taiwan, Australia, Singapore, China
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma

United States, Taiwan, Australia
Northwestern University
National Cancer Institute (NCI)

Recruiting

Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

Locally Advanced Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Oncocytic Carcinoma

United States
Clinique Beau Soleil
Cepheid; Team Languedoc Mutualité / Nouvelles technologies

Completed

Diagnostic Performance Evaluation Study of the Xpert® Bladder Cancer Monitor Test. (Xpert Bladder)

Non-Invasive Bladder Urothelial Carcinoma | Non-Invasive Bladder Papillary Urothelial Carcinoma, Low Grade | Non-Invasive Bladder Papillary Urothelial Carcinoma, High Grade

France
M.D. Anderson Cancer Center

Recruiting

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

Thyroid Gland Anaplastic Carcinoma | Thyroid Gland Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma

United States
Saint Petersburg State University, Russia

Withdrawn

Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer (ANAPLAST-NEO)

Thyroid Gland Anaplastic Carcinoma

Russian Federation
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma

United States
Vancouver Coastal Health

Unknown

123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors

Neuroblastoma | Pheochromocytoma | Paraganglioma | Medullary Thyroid Carcinoma | Carcinoid Tumors

Canada
Providence Health & Services

Recruiting

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

BRAF V600E Mutation Present | Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8 | Refractory Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | BRAF NP_004324.2:p.V600M | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8 | Stage IVB Differentiated Thyroid Gland Carcinoma...

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer

Thyroid Gland Anaplastic Carcinoma

United States
Umraniye Education and Research Hospital

Unknown

Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort

Thyroid Neoplasms | Thyroid Cancer, Papillary | Vocal Cord Paralysis | Thyroid Cancer | Thyroid Nodule | Vocal Cord Paresis | Multinodular Goiter | Iatrogenic Hypocalcemia | Calcium Deficiency | Iatrogenic Hypoparathyroidism | Vocal Cord; Injury, Superficial | PTH

Turkey
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management

Advanced Thyroid Gland Medullary Carcinoma | Stage III Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IV Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IVC Thyroid Gland Medullary...

United States
Beijing Scitech-Mq Pharmaceuticals Limited

Recruiting

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer

Differentiated Thyroid Carcinoma

China
Grupo Español de Tratamiento de Tumores de Cabeza...

Active, not recruiting

Spanish Study for Molecular Characterization of Thyroid Carcinoma (MOLTHY)

Differentiated Thyroid Carcinoma | Medullary Thyroid Carcinoma

Spain
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Thyroid Gland Anaplastic Carcinoma | BRAF V600K Mutation Present | BRAF NP_004324.2:p.V600E

United States
AstraZeneca
SCRI Development Innovations, LLC

Completed

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Papillary Renal Cell Cancer

United States, Canada, United Kingdom, Spain
Tianjin Medical University Cancer Institute and...

Unknown

Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma

Differentiated Thyroid Carcinoma

China
Oncology Institute of Southern Switzerland

Completed

OnT4-Thyroglobulin Assay Before rhTSH-Aided Radioiodine Ablation

Differentiated Thyroid Carcinoma
Memorial Sloan Kettering Cancer Center

Recruiting

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

Thyroid Carcinoma | Metastatic Thyroid Carcinoma

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma

Poorly Differentiated Thyroid Carcinoma

China
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

Multiple Endocrine Neoplasia Type 2A | Multiple Endocrine Neoplasia Type 2B | Recurrent Thyroid Gland Medullary Carcinoma | Hereditary Thyroid Gland Medullary Carcinoma | Locally Advanced Thyroid Gland Medullary Carcinoma | Sporadic Thyroid Gland Medullary Carcinoma | Stage III Thyroid Gland Medullary... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer

Thyroid Gland Undifferentiated (Anaplastic) Carcinoma

United States
University Medical Center Groningen

Recruiting

Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer (MIMETIC)

Medullary Thyroid Cancer | Thyroid Cancer, Medullary | Medullary Thyroid Carcinoma | Thyroid Carcinoma, Medullary

Netherlands
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Terminated

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

Solid Tumor | Thyroid Cancer

United States
Eisai Inc.

Terminated

A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Thyroid Carcinoma, Anaplastic

Italy, United States, France, Australia, United Kingdom
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

Medullary Thyroid Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

CEUS Improves the Diagnostic Performance of SRSS of Thyroid Carcinoma

Thyroid Carcinoma | Thyroid Nodule

China
Kenneth Ain
Celgene Corporation

Completed

REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas

Thyroid Neoplasms

United States
National Cancer Institute (NCI)

Terminated

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

Medullary Thyroid Carcinoma

United States
Hutchison Medipharma Limited

Completed

Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma

Thyroid Carcinoma

China
Bayer

Completed

Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients

Thyroid Carcinoma

Japan
Peking Union Medical College Hospital

Not yet recruiting

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma

China
Genzyme, a Sanofi Company

Completed

Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma

Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma

Japan
University of Wuerzburg
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer (CLERAD-PROBE)

Differentiated Thyroid Carcinoma

Germany
Grupo Espanol de Tumores Neuroendocrinos
Gilead Sciences; MFAR

Not yet recruiting

Sacituzumab govitEcan in THYroid Cancers (SETHY)

Differentiated Thyroid Cancer | Anaplastic Thyroid Cancer

Spain
Memorial Sloan Kettering Cancer Center
AstraZeneca

Completed

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Metastatic Anaplastic Thyroid Cancer

United States
National University Hospital, Singapore
Singapore General Hospital

Unknown

Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy

Thyroid Cancer

Singapore
Hospices Civils de Lyon

Active, not recruiting

Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)

Thyroid Cancer

France
The Catholic University of Korea

Completed

Hürthle Cell Carcinoma and Follicular Thyroid Carcinoma (HCC and FTC)

Huerthle Cell Carcinoma

Clinical Trials on Carcinome papillaire de la thyroïde

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations